S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
All the trading advice you’ve ever received boils down to this (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
All the trading advice you’ve ever received boils down to this (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
All the trading advice you’ve ever received boils down to this (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
All the trading advice you’ve ever received boils down to this (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
All the trading advice you’ve ever received boils down to this (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)

Editas Medicine Stock Price, News & Analysis (NASDAQ:EDIT)

$10.77
+0.24 (+2.28%)
(As of 12/1/2023 ET)
Compare
Today's Range
$10.31
$10.85
50-Day Range
$6.25
$10.84
52-Week Range
$6.08
$11.93
Volume
1.90 million shs
Average Volume
1.90 million shs
Market Capitalization
$879.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.92

Editas Medicine MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
29.2% Upside
$13.92 Price Target
Short Interest
Healthy
19.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.63
Upright™ Environmental Score
News Sentiment
0.54mentions of Editas Medicine in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$2,076 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.40) to ($2.55) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

339th out of 957 stocks

Biological Products, Except Diagnostic Industry

54th out of 161 stocks


EDIT stock logo

About Editas Medicine Stock (NASDAQ:EDIT)

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

EDIT Stock Price History

EDIT Stock News Headlines

Editas Medicine Inc EDIT
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
CRISPR-Cas9 Gene Editing Is On The Cusp Of Something Big
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
RBC Capital Keeps Their Hold Rating on Editas Medicine (EDIT)
Editas Medicine spikes after Q3 results
Editas Medicine Q3 2023 Earnings Preview
Citigroup Upgrades Editas Medicine (EDIT)
See More Headlines
Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2023
Today
12/03/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/28/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EDIT
Fax
N/A
Employees
226
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.92
High Stock Price Target
$30.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+29.2%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
12 Analysts

Profitability

Net Income
$-220,430,000.00
Net Margins
-792.70%
Pretax Margin
-792.70%

Debt

Sales & Book Value

Annual Sales
$19.71 million
Book Value
$4.41 per share

Miscellaneous

Free Float
79,877,000
Market Cap
$879.59 million
Optionable
Optionable
Beta
1.96
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Gilmore O'Neill (Age 59)
    President, CEO & Director
    Comp: $815.37k
  • Dr. Bruce E. Eaton Ph.D. (Age 69)
    Executive VP, CTO & Chief Business Officer
    Comp: $786.23k
  • Dr. Baisong Mei M.D.
    Ph.D., Senior VP & Chief Medical Officer
  • Dr. Feng Zhang Ph.D.
    Co-Founder & Scientific Advisory Board Member
  • Dr. George McDonald Church Ph.D. (Age 69)
    Co-Founder & Scientific Advisory Board Member
  • Dr. J. Keith Joung M.D.
    Ph.D., Co-Founder & Scientific Advisory Board Member
  • Dr. David R. Liu Ph.D.
    Co-Founder & Scientific Advisory Board Member
  • Mr. Erick J. Lucera C.F.A. (Age 55)
    CPA, CFO & Executive VP
  • Mr. Harry R. Gill III (Age 62)
    Senior Vice President of Operations
  • Dr. Linda C. Burkly Ph.D.
    Executive VP & Chief Scientific Officer














EDIT Stock Analysis - Frequently Asked Questions

Should I buy or sell Editas Medicine stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View EDIT analyst ratings
or view top-rated stocks.

What is Editas Medicine's stock price target for 2024?

12 brokerages have issued 1-year price targets for Editas Medicine's stock. Their EDIT share price targets range from $7.00 to $30.00. On average, they expect the company's share price to reach $13.92 in the next year. This suggests a possible upside of 29.2% from the stock's current price.
View analysts price targets for EDIT
or view top-rated stocks among Wall Street analysts.

How have EDIT shares performed in 2023?

Editas Medicine's stock was trading at $8.87 on January 1st, 2023. Since then, EDIT shares have increased by 21.4% and is now trading at $10.77.
View the best growth stocks for 2023 here
.

Are investors shorting Editas Medicine?

Editas Medicine saw a decrease in short interest in November. As of November 15th, there was short interest totaling 15,870,000 shares, a decrease of 5.4% from the October 31st total of 16,770,000 shares. Based on an average daily trading volume, of 1,630,000 shares, the short-interest ratio is currently 9.7 days.
View Editas Medicine's Short Interest
.

When is Editas Medicine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our EDIT earnings forecast
.

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) announced its quarterly earnings data on Friday, November, 3rd. The company reported ($0.55) EPS for the quarter, beating analysts' consensus estimates of ($0.64) by $0.09. The firm earned $5.34 million during the quarter, compared to analyst estimates of $3.70 million. Editas Medicine had a negative net margin of 792.70% and a negative trailing twelve-month return on equity of 54.24%. The company's revenue for the quarter was up 1171.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.81) earnings per share.

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

When did Editas Medicine IPO?

(EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by many different retail and institutional investors. Top institutional shareholders include Northern Trust Corp (1.09%), Charles Schwab Investment Management Inc. (0.84%), Rafferty Asset Management LLC (0.69%), Mirae Asset Global Investments Co. Ltd. (0.46%), Bank of New York Mellon Corp (0.38%) and Barclays PLC (0.34%). Insiders that own company stock include Baisong Mei, Bruce Eaton, Charles Albright, Gilmore Neil O'neill, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson.
View institutional ownership trends
.

How do I buy shares of Editas Medicine?

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:EDIT) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -